Half-year Report | 26-Sep-2024 | 07:00 | RNS |
Exclusive agreement for DNA NGS panel | 23-Sep-2024 | 07:00 | RNS |
Notice of Interim Results and Webcast | 17-Sep-2024 | 07:00 | RNS |
Standard form for notification of major holdings | 18-Jul-2024 | 10:08 | RNS |
Standard form for notification of major holdings | 12-Jul-2024 | 15:38 | RNS |
Result of 2024 Annual General Meeting | 11-Jul-2024 | 15:07 | RNS |
Result of open offer | 21-Jun-2024 | 07:00 | RNS |
Posting of 2023 Annual Report & Notice of the AGM | 18-Jun-2024 | 14:41 | RNS |
Publication of Circular | 06-Jun-2024 | 16:37 | RNS |
Results of placing and subscription | 05-Jun-2024 | 16:04 | RNS |
Proposed Placing, Subscription and Open Offer | 05-Jun-2024 | 07:00 | RNS |
Preliminary Results | 05-Jun-2024 | 07:00 | RNS |
New commercial agreement with large pharma | 03-May-2024 | 07:00 | RNS |
New commercial agreement with AstraZeneca | 24-Apr-2024 | 07:00 | RNS |
US and EU patents for innovative CellKeep™... | 22-Apr-2024 | 07:00 | RNS |
Currency | UK Pounds |
Share Price | 8.25p |
Change Today | 0.25p |
% Change | 3.13 % |
52 Week High | 31.35 |
52 Week Low | 7.25 |
Volume | 834,348 |
Shares Issued | 322.64m |
Market Cap | £26.62m |
Beta | 0.62 |
RiskGrade | 312 |
Value |
---|
Price Trend |
---|
Income |
---|
Growth |
---|
Strong Buy | 1 |
Buy | 0 |
Neutral | 0 |
Sell | 0 |
Strong Sell | 0 |
Total | 1 |
No dividends found |
Time | Volume / Share Price |
15:24 | 5,982 @ 8.30p |
15:18 | 19,607 @ 8.09p |
15:08 | 395 @ 8.06p |
14:12 | 42,929 @ 8.08p |
13:45 | 5,982 @ 8.30p |
CEO | Andrew D Newland |
Finance Director | Ian F Griffiths |
Chair | Jan Groen |
You are here: research